RA
AMRI

Royce & Associates’s Albany Molecular Research Inc AMRI Stock Holding History

Royce & Associates’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-396,275
Closed -$8.6M – 1285
2017
Q2 		$8.6M Sell
396,275
-1,122,001
-74% -$20.4M 0.06% 429
2017
Q1 		$21.3M Buy
1,518,276
+227,365
+18% +$3.72M 0.14% 201
2016
Q4 		$24.2M Buy
1,290,911
+36,615
+3% +$622K 0.16% 183
2016
Q3 		$20.7M Buy
1,254,296
+70,327
+6% +$1.04M 0.14% 204
2016
Q2 		$15.9M Buy
1,183,969
+104,500
+10% +$1.52M 0.11% 263
2016
Q1 		$16.5M Buy
1,079,469
+93,254
+9% +$1.46M 0.1% 263
2015
Q4 		$19.6M Sell
986,215
-105,101
-10% -$2M 0.12% 231
2015
Q3 		$19M Sell
1,091,316
-128,000
-10% -$2.61M 0.1% 251
2015
Q2 		$24.7M Sell
1,219,316
-71,900
-6% -$1.39M 0.1% 250
2015
Q1 		$22.7M Buy
1,291,216
+55,200
+4% +$941K 0.09% 296
2014
Q4 		$20.1M Buy
1,236,016
+93,346
+8% +$1.71M 0.07% 355
2014
Q3 		$25.2M Sell
1,142,670
-172,940
-13% -$3.54M 0.09% 289
2014
Q2 		$26.5M Sell
1,315,610
-29,000
-2% -$491K 0.08% 311
2014
Q1 		$25M Sell
1,344,610
-67,958
-5% -$936K 0.07% 317
2013
Q4 		$14.2M Buy
1,412,568
+417,858
+42% +$5.05M 0.04% 531
2013
Q3 		$12.8M Sell
994,710
-109,000
-10% -$1.34M 0.04% 544
2013
Q2 		$13.1M Buy
+1,103,710
New +$12M 0.04% 522

Other funds holding AMRI

AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Royce & Associates's AMRI Position: Q3 2017 in Review

Royce & Associates sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 396,275 shares — an estimated $8.6M sold.

Royce & Associates first reported a position in AMRI in Q2 2013 and held it in 17 quarters. The position peaked at $26.5M in Q2 2014. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.

  • Royce & Associates reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
  • Royce & Associates sold 396,275 Albany Molecular Research Inc shares in Q3 2017, an estimated $8.6M.
  • Royce & Associates first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 17 quarters.
  • Royce & Associates's Albany Molecular Research Inc position peaked at $26.5M in Q2 2014.
  • 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.

Based on Royce & Associates's 13F filing for Q3 2017, filed 13 Nov 2017.